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Abstract 
The growing field of cardio-oncology addresses the side effects of cancer treatment on the 
cardiovascular system. Here, we explored the cardiotoxicity of the antiangiogenic therapy, 
sunitinib, in the mouse heart from a diagnostic and therapeutic perspective. 
We showed that sunitinib induces an anaerobic switch of cellular metabolism within the 
myocardium which is associated with the development of myocardial fibrosis and reduced left 
ventricular ejection fraction as demonstrated by echocardiography. The capacity of positron 
emission tomography with [18F]fluorodeoxyglucose to detect the changes in cardiac metabolism 
caused by sunitinib was dependent on fasting status and duration of treatment. Pan proteomic 
analysis in the myocardium showed that sunitinib induced (i) an early metabolic switch with 
enhanced glycolysis and reduced oxidative phosphorylation, and (ii) a metabolic failure to use 
glucose as energy substrate, similar to the insulin resistance found in type 2 diabetes. 
Co-administration of the endothelin receptor antagonist, macitentan, to sunitinib-treated animals 
prevented both metabolic defects, restored glucose uptake and cardiac function, and prevented 
myocardial fibrosis.  
These results support the endothelin system in mediating the cardiotoxic effects of sunitinib and 
endothelin receptor antagonism as a potential therapeutic approach to prevent cardiotoxicity.  
Furthermore, metabolic and functional imaging can monitor the cardiotoxic effects and the 
benefits of endothelin antagonism in a theranostic approach. 
Key words: cardio-oncology, cardiotoxicity, positron emission tomography, echocardiography, endothelin, 
sunitinib, macitentan. 
Introduction 
The major factor limiting therapeutic 
administration of anticancer drugs is their toxic side 
effect on off-target organs. It is well known that 
classical anticancer drugs, e.g. anthracyclines, 
antimetabolites, alkylating agents, taxanes, induce 
serious cardiovascular toxicity (1, 2). Newer 
anticancer agents such as interferon and tyrosine 
kinase receptor (TKR) inhibitors also have 
cardiovascular side-effects (3) that, although often less 
severe than those observed with anthracyclines, are 
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frequent and may be life-threatening (4). The clinical 
importance of cardiotoxicity associated with cancer 
therapy has led to the emergence of cardio-oncology, an 
interdisciplinary field that aims to better understand 
and limit the cardiotoxicity of cancer therapy (5).  
Anti-angiogenics targeting the Vascular 
Endothelial Growth Factor Receptors (VEGFRs) 
pathway are considered as an essential asset for 
cancer treatment given the importance of the 
neovascularization process in tumor development 
(6,7). However, they are associated with a spectrum of 
cardiovascular side effects (8). The major 
treatment-limiting side effects of antiangiogenic TKR 
inhibitors include nausea, fatigue, hypertension, 
myocardial infarction, left ventricular cardiac and 
renal dysfunction, QT prolongation, neutropenia, 
proteinuria, thyroid impairment, thrombosis and 
hemorrhage (9–12).  
Sunitinib (Sutent; Pfizer, USA) is an 
anti-angiogenic TKR inhibitor of VEGFRs, 
platelet-derived growth factor receptors (PDGF-Rs), 
and c-kit (13), approved in 2006 by the FDA for the 
treatment of renal cell carcinoma (14), 
imatinib-resistant gastrointestinal stromal tumor (15) 
and neuroendocrine tumors (16). In 2007, a study 
reported hypertension in ~50% of sunitinib-treated 
patients (8), decreased left ventricular ejection fraction 
(LVEF) in ~30% of patients, and congestive heart 
failure in ~10% of imatinib-resistant patients treated 
with sunitinib (8). Regarding sunitinib-induced 
hypertension, Lankhorst et al. listed as plausible 
mechanisms: deregulation of the nitric oxide signaling 
pathway, microvascular rarefaction, activation of 
endothelin (ET) system, salt sensitivity and oxidative 
stress (17). However, there are contradictory reports 
on the potential of sunitinib to up- or downregulate 
the nitric oxide pathway (17) and to cause 
microvascular rarefaction (18). Several lines of 
evidence suggest that the cardiotoxic effects of 
sunitinib are not only mediated by the development 
of hypertension but also through direct effects on the 
heart (8, 19). Inhibition of myocardial VEGFRs 
reduces response to stress, activates the pro-apoptotic 
pathway and maintains a high level of HIF-1α that is 
known to induce cardiomyopathy (20). Inhibition of 
PDGFRs by sunitinib induces a loss of coronary 
microvascular pericytes, suggesting a possible direct 
effect of sunitinib on myocardial blood supply (19). In 
rats, sunitinib leads to mitochondrial dysfunction; in 
mice, to increased apoptosis of cardiomyocytes (8). Ex 
vivo, a poor coronary flow response to bradykinin was 
reported in sunitinib-treated hearts, supporting 
microvascular dysfunction as a direct cardiac side 
effect of the drug (21). Finally, the fact that sunitinib 
inhibits AMPK (22) and induces mitochondrial 
damage (8) opens up the possibility that some or all of 
its side effects could result from a direct deregulation 
of cardiac metabolism.  
Elevated plasma levels of endothelin-1 (ET-1) are 
found in animals and patients treated with sunitinib 
(21). An activated ET system likely contributes to 
vasoconstriction, hypertension, renal injury and 
proteinuria (23). Previous studies have shown that ET 
receptor blockers can reduce blood pressure (BP) and 
renal injury in animals and patients treated with 
sunitinib (21, 23–25). However, to our knowledge, the 
potential benefits of ET receptor antagonism in 
treating (or preventing) the cardiotoxic effects of 
sunitinib have not been studied. 
Clinical imaging of the heart is a method of 
choice to explore the cardiac side effects of anticancer 
therapy (26). Echocardiography and magnetic 
resonance imaging (MRI) show reduced left 
ventricular ejection fraction (LVEF) in advanced 
stages of cardiotoxicity (27). In fact, most imaging 
studies have focused on the late stages of 
cardiotoxicity, either because imaging was prescribed 
after the clinical signs became evident, or because 
imaging failed to detect earlier signs. Nevertheless, a 
few studies have shown the capacity of nuclear 
imaging techniques to assess early cardiotoxicity 
associated with anthracyclines and trastuzumab (28). 
Borde et al. described a higher uptake of 
2'-deoxy-2'-[18F]fluoro-D-glucose (FDG) in the 
myocardium of patients treated with adriamycin, 
highlighting the capacity of positron emission 
tomography (PET) to detect a deregulation of 
myocardial metabolism induced by a cancer 
treatment (29). Recently, O’Farrell et al. described an 
early increase of the metabolic rate of glucose in 
sunitinib-treated rodents (30). This is particularly 
interesting from a clinical perspective as PET can 
simultaneously stage cancer and explore cardiac 
metabolism. 
Here, we explored cardiac metabolism after 
sunitinib treatment in mice using PET-FDG. We 
aimed to (i) better clarify the cardiac metabolic 
pathways deregulated during the early stages of 
sunitinib treatment, (ii) determine if the cardiac side 
effects are mediated by the endothelin pathway (iii) 
test the hypothesis that blockade of the endothelin 
system would prevent the cardiac side effects of 
sunitinib, and (iv) confirm that PET FDG can be useful 
to monitor cardiac metabolic remodeling.  
Results  
The study design followed a standard protocol 
of mouse oncology studies for monitoring of 
short-term response to therapy with PET in fasted, 
tumor-bearing, nude mice (Figure 1A). The same 
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protocol was repeated in C57BL/6 immunocompetent 
mice with addition of echocardiography (Figure 1B). 
In another group of C57BL/6 mice, treatment 
duration was extended to three weeks (Figure 1C). 
Histology and proteome analysis were performed in 
all groups after treatment completion. 
Sunitinib increases myocardial FDG uptake  
After 5 days of sunitinib treatment, a 
significantly higher accumulation of FDG in the heart 
of fasted tumor-bearing nude mice was observed than 
in the vehicle group (Figure 2A). Compared to 
baseline, the mean standard uptake value (SUV) 
increased in the sunitinib group whereas it remained 
unchanged in the vehicle group (p <0.001, Figure 2B). 
Similar results were obtained in non-tumorized 
immunocompetent C57BL/6 mice using the same 
protocol: 5 days of sunitinib significantly increased 
FDG uptake compared to baseline (p <0.05; Figure 
2B). Dynamic PET scans obtained under fasting 
conditions confirmed that sunitinib increased cardiac 
FDG metabolic flux in nude and C57BL/6 mice 
(Figure 2C). These findings support a 
sunitinib-induced shift towards glycolysis. 
Accordingly, hearts from sunitinib-treated mice 
showed a trend for higher expression of the glucose 
transporter protein GLUT1 and of Hexokinase II, the 
glucose phosphorylating enzyme, together with 
reduced expression of PGC1α, a key regulator of 
energy metabolism (Figure 3E). Moreover, 5 days of 
sunitinib treatment in C57BL/6 mice raised cardiac 
FDG uptake and lowered cardiac output (p <0.05, 
sunitinib vs. vehicle) (Figure 2D).  
Sunitinib-induced increased myocardial FDG 
uptake is associated with increased cardiac 
fibrosis  
We then explored whether the sunitinib-induced 
increase in FDG uptake was associated with a direct 
effect on the cardiac microvasculature, but found no 
difference in vessel density after sunitinib treatment 
(Figure 3A - 3B). This is in keeping with previous 
studies that have shown that microvascular 
rarefaction is not responsible for sunitinib-induced 
coronary dysfunction (19). By contrast, sunitinib 
treatment significantly increased myocardial fibrosis 
compared to hearts from vehicle-treated mice 
(p<0.001 and p<0.01 for nude and C57BL/6 mice, 
respectively) (Figure 3C - 3D).  
 
 
Figure 1. Study design: (A) represents investigation for short-term cardiotoxic effects on immunodeficient tumor-bearing mice (nude). Sunitinib-treated mice were studied 
at baseline and week 1 using a cancer PET protocol compared to vehicle. (B) represents investigation for short-term cardiotoxic effects on immunocompetent mice (C57BL/6). 
Sunitinib-treated mice were studied at baseline and week 1 using a cancer PET protocol and echocardiography compared to vehicle. (C) represents study design for long-term 
treatment on immunocompetent mice (C57BL/6). Sunitinib-treated mice were followed at baseline, week 1, week 2 and week 3 using a cardiac PET protocol and 
echocardiography compared to vehicle and sunitinib+macitentan groups. FDG: 2'-deoxy-2'-[18F]fluoro-D-glucose. 
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Sunitinib downregulates oxidative energy 
metabolism pathways 
Label-free pan-analysis of protein expression in 
mouse hearts revealed that 5 days of sunitinib 
treatment led to a significant downregulation of major 
oxygen-dependent metabolic pathways, including 
isocitrate dehydrogenase and succinate 
dehydrogenase (both enzymes of the tricarboxylic 
acid (TCA) cycle), phosphoenolpyruvate 
carboxykinase (first enzyme of gluconeogenesis), 
phosphoglycerate mutase and phosphorylase B 
kinase (key enzymes of carbohydrate metabolism) 
and carnitine O-palmitoyltransferase (mitochondrial 
transporter of fatty acids). All the proteins for which 
we found different levels of expression in the 
sunitinib and vehicle groups are listed in Table 1. 
Ingenuity® analysis highlighted that sunitinib 
treatment induced mitochondrial dysfunction and a 
clear switch towards anaerobic glycolytic metabolism, 
similar to the one seen during cardiac hypertrophy 
(31). In particular, proteins of the fatty acid 
degradation pathway such as acyl-CoA 
dehydrogenase (Acad8), phospholipases, and fatty 
acid transferases, those controlling glycogen 
breakdown (Pgam1, Me3) and the synthesis of the 
cofactor flavine adenine dinucleotide (FAD) were 
reduced in sunitinib-treated hearts. Taken together, 
these results are in agreement with a switch towards 
the utilization of glucose as major energy 
source and with the activation of glycolysis in 
the myocardium of sunitinib-treated mice 
evidenced by increased FDG uptake.  
The effect of sunitinib on cardiac FDG 
uptake depends on glucose metabolism 
of the heart 
Cardiac FDG uptake varies widely with 
plasmatic concentrations of glucose and 
insulinemia, hence with the post-prandial 
time. Oncology PET scans are performed in 
fasted patients and animals in order to reduce 
the cardiac uptake of FDG in oncology 
studies and better delineate the tumor 
uptake. Conversely, imaging of glucose 
metabolism in the heart is often performed 
under an euglycemic clamp (glucose plus 
insulin administration) in order to increase 
metabolism of glucose and FDG uptake in the 
heart. Since sunitinib has been shown to 
induce hypoglycemia in patient and animal 
studies (32), we tested whether the effect of 
the drug on cardiac FDG uptake would differ 
in fasted versus non-fasted mice. 
Interestingly, in contrast to fasted mice, the 
FDG SUV were similar in sunitinib and 
vehicle-treated non-fasted animals after 1 and 
3 weeks of treatment (Figure 4A). However, 
the effects of sunitinib on heart function were 
maintained in non-fasted animals, i.e. cardiac 
output was reduced after 1 and 3 weeks of 
sunitinib with respect to pre-sunitinib 
baseline values (Figure 4B), with significant 
reductions in diastolic (Figure 4C) and stroke 
volumes. Sunitinib also significantly reduced 
blood flow as shown by the fall in aortic flow 
(aortic velocity tracking integral) (Figure 4D). 
 
Figure 2. Sunitinib increases myocardial FDG uptake in fasted mice: (A) Example of PET 
scan images representing cardiac views of FDG-SUV at baseline (left) and post-treatment (right) in 
vehicle-treated mice and sunitinib-treated mice. (B) Difference post-treatment – baseline of 
myocardial FDG-SUV for sunitinib and vehicle groups in nude mice (n=6 for vehicle, n=10 for 
sunitinib) and C57BL/6 (n=6 for each). (C) Difference post-treatment – baseline of myocardial 
metabolic flux for sunitinib and vehicle groups in nude mice (n=5 for vehicle, n=10 for sunitinib) and 
C57BL/6 (n=2 for each). (D) Difference in cardiac output (CO, Heart Rate times stroke volume) for 
sunitinib and vehicle in C57BL/6 mice (n=8 for each groups). Data expressed as mean±SEM; *p 
<0.05 compared to baseline, **p <0.01 and ***p <0.001 compared to baseline, $p <0.05 compared 
to vehicle. CO: cardiac output; SUV: standard uptake values 
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Figure 3. Sunitinib-induced increased FDG uptake in fasted mice is associated with increased fibrosis: (A) Representative sections of myocardium stained for 
blood vessels (lsolectine B4 Griffonia Simplicifolia-FITC, green) and nuclei (DAPI, blue). (B) Quantification of microvascular density normalized by cell number in nude and 
C57Bl/6 mice treated with vehicle (open circles) or sunitinib (black circles). (C) Representative sections of myocardium stained for fibrosis (Picrosirius red) from hearts of mice 
treated with vehicle (left) or sunitinib (right). (D) Quantification of fibrosis (normalized by tissue area) in nude and C57Bl/6 mice treated with vehicle (open circles) or sunitinib 
(filled circles). (E) Representative blots and their associated quantification for GLUT1, HK2 and PGC1α (normalized by cyclophilin B) mice treated with vehicle (open circles) or 
sunitinib (filled circles). Data expressed as mean ± SEM; $$p <0.01 $$$p <0.001 compared to vehicle. HK2: Hexokinase 2; GLUT1: glucose transporter 1; PGC1α; Peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha; S: sunitinib; V: vehicle. 
 
Endothelin receptor antagonism prevents 
sunitinib-induced diastolic dysfunction and 
myocardial flux dysfunction  
It has been demonstrated that the endothelin 
(ET) pathway mediates the hypertension and renal 
complications of sunitinib (24). Macitentan, a 
clinically-available mixed ETA and ETB receptor 
antagonist, was given concomitantly with sunitinib to 
mice during 3 weeks. A comparison of protein 
expression in the sunitinib-treated group with that in 
the vehicle group and sunitinib plus macitentan 
group evidenced the protective effects of macitentan 
on diastolic dysfunction. This was confirmed by 
expression levels of several actin and myosin protein 
isoforms and associated fibrillar protein, for which 
macitentan countered the effect of sunitinib on their 
level of expression (Table 2). It should be noted that 
macitentan treatment normalized both the diastolic 
volume and the cardiac output, allowing the 
maintenance of aortic flow (Figure 4B - 4D). 
Kinetics analysis of dynamic FDG-PET scans of 
the heart showed a trend towards a higher metabolic 
flux and a higher metabolic rate of glucose (MRGlu) 
after 1 and 2 weeks of sunitinib treatment that did not 
reach statistical significance (Figure 5A). In contrast, 
both parameters were significantly reduced after 3 
weeks of sunitinib, showing that the early promotion 
of cardiac glycolysis by sunitinib was followed by a 
secondary drop in glucose utilization. Macitentan 
plus sunitinib co-administration maintained 
metabolic flux and MRGlu to their pre-treatment 
baseline levels after 3 weeks of treatment (Figure 5A). 
In line with our previous observations at 1 week of 
treatment, 3 weeks of sunitinib was not associated 
with any change in myocardial vessel density (Figure 
5B – 5C). A proteomics analysis of the macitentan and 
sunitinib treated hearts and comparison with the 
sunitinib-only or vehicle-treated groups confirmed 
the protective effects of endothelin antagonism by 
macitentan on endothelial cell dysfunction (Table 2). 
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Table 1. Major changes in protein expression levels of the myocardium after one week of treatment 
Categories Protein name Gene ID   sunitinib versus vehicle 
 p-value FC 
Glucogenolysis Phosphoglycerate mutase 1 Pgam1   0.01 -1.28 
Glucogenolysis NADP-dependent malic enzyme 3, mitochondrial Me3   0.01 -1.17 
TCA cycle Isobutyryl-CoA dehydrogenase, mitochondrial Acad8  < 0.001 -1.30 
TCA cycle Pyruvate dehydrogenase (acetyl-transferring) kinase isozyme 2, mitochondrial Pdk2  0.08 -1.21 
TCA cycle Isocitrate dehydrogenase [NAD] subunit gamma 1, mitochondrial Idh3g  0.03 -1.24 
TCA cycle Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial Idh3a  0.05 -1.14 
TCA cycle Succinate dehydrogenase complex flavoprotein subunit A, mitochondrial Sdha  0.02 -1.12 
AMPK Phosphoenolpyruvate carboxykinase 2, mitochondrial Pck2   < 0.0001 - 
AMPK Carnitine O-palmitoyltransferase 1, muscle isoform Cpt1b   0.21 -1.19 
Hypertrophy Carnitine O-palmitoyltransferase 1, liver isoform Cpt1a  0.04 -1.31 
Hypertrophy Phospholipase C beta 3 Plcb3  0.01 - 
Hypertrophy Transforming protein RhoA RhoA  0.02 -1.59 
Hypertrophy Caveolin-1 Cav1  0.04 -1.30 
Hypertrophy Telethonin Tcap  < 0.01 -1.70 
Hypertrophy A-kinase anchor protein 1, mitochondrial Akap1  0.02 -1.45 
Mitochondria Heat shock protein beta-1 Hspb1   0.02 -1.23 
Mitochondria Heat shock 70 kDa protein 4L Hspa4l   0.01 -1.44 
Mitochondria Mitochondrial import receptor subunit TOM70 Tomm70a   0.06 -1.27 
Mitochondria Electron transfer flavoprotein dehydrogenase Etfdh   0,04 -1.34 
Mitochondria Sulfite oxidase, mitochondrial Suox   0.02 1.22 
Energy metabolism  NAD-dependent protein deacetylase sirtuin-4 Sirt4  - - 
Energy metabolism  PGC-1 and ERR-induced regulator in muscle protein 1 Perm1  0.09 -1.35 
Hypoxia ubiquitin specific peptidase 19 Usp19   < 0.0001 - 
Hypoxia Hypoxia up-regulated protein 1 Hyou1   0.06 1.26 
Nitric oxide Guanylate cyclase soluble subunit beta-1 Gucy1b3   0.03 -1.55 
Oxidative stress Glutathione reductase, mitochondrial Gsr   0.02 1.41 
Glycometabolism 1-acylglycerol-3-phosphate O-acyltransferase 2 Agpat2  < 0.001 -2.13 
Glycometabolism Dolichyl-diphosphooligosaccharide-non-catalytic subunit Ddost  0.02 1.15 
Glycometabolism CDP-diacylglycerol--inositol 3-phosphatidyltransferase Cdipt  0.02 1.63 
 Sodium-dependent phosphate transporter 2 Slc20a2  0.03 -1.28 
 Sodium/potassium-transporting ATPase subunit beta-1 Atp1b1  0.03 -1.31 
 Flavin adenine dinucleotide synthetase 1 Flad1  0.03 -1.29 
  Pirin Pir   0.04 - 
Results from Label-free protein quantification showing the ratios of protein expression levels in sunitinib versus vehicle. Numbers indicate the fold change (FC) between two 
groups and the p-value of the two tailed Student t.test. The sign “–“ indicates undetected protein in the denominator. group. n=3 for each. AMPK: 5' AMP-activated protein 
kinase; cdp: cytidine diphospho; ERR: estrogen-related receptor; NAD: nicotinamide adenine dinucleotide; NADP: nicotinamide adenine dinucleotide phosphate; PGC-1: 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha; TCA: tricarboxylic acid.  
 
 
Figure 4. Macitentan prevents sunitinib-induced diastolic dysfunction. (A) Difference treatment – baseline of myocardial FDG-SUV for vehicle (n=9), sunitinib (n=10) 
and sunitinib+macitentan treated mice (n=8) at week 1 and week 3. (B) Difference treatment – baseline values of CO is represented for vehicle (n=7), sunitinib (n=10) and 
sunitinib+macitentan (n=8) groups at week 1 and 3. (C) Difference treatment – baseline of left ventricular internal diameter at diastole for the three groups. (D) Difference 
treatment – baseline of aortic velocity time integral for both groups. Data are expressed as mean ± SEM, *p <0.05 compared to baseline, ***p <0.001 compared to baseline, $p 
<0.05 compared to other at week 3. AoVTI: Aortic velocity tracking integral; CO: cardiac output; LVID: left ventricular internal diameter; SUV: standard uptake value. 
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Table 2. Major changes in protein expression levels of the myocardium after three weeks of treatments 
      sunitinib versus 
vehicle 
sunitinib versus 
sunitinib + 
macitentan 
sunitinib + 
macitentan 
versus vehicle 
Categories Protein ID p-value FC p-value FC p-value FC 
Glucogenolysis facilitated glucose transporter member 4 Slc2a4 0,009 7,78 0,219 1,57 0,024 4,97 
Glucogenolysis RAB10, member RAS oncogene family Rab10 0,071 -1,30 0,405 1,07 0,030 -1,39 
Glycogen, IR 1,4-alpha-glucan-branching enzyme 1 Gbe1 0,038 -1,22 0,010 -1,23 0,908 1,01 
Glucogenolysis Acyl-CoA dehydrogenase family member 9 Acad9 0,010 -1,18 0,114 -1,11 0,172 -1,06 
Glucogenolysis phosphorylase, glycogen, muscle Pygm 0,046 -1,14 0,213 -1,09 0,424 -1,05 
Glucogenolysis Glucose-6-phosphate isomerase Gpi 0,003 1,15 0,276 -1,07 0,003 1,23 
Glucogenolysis Glucose-6-phosphate 1-dehydrogenase G6pdx 0,855 -1,09 0,360 1,98 0,015 -2,17 
Glucogenolysis Phosphofructokinase, muscle Pfkm 0,071 -1,20 0,959 1,00 0,071 -1,20 
Glucogenolysis phosphofructokinase, platelet Pfkp 0,024 1,26 0,013 -1,42 0,001 1,79 
Glucogenolysis Phosphoglycerate mutase 1 Pgam1 0,011 1,48 0,141 1,18 0,057 1,26 
Glucogenolysis Glyceraldehyde-3-phosphate dehydrogenase Gapdh 0,074 -1,12 0,043 -1,24 0,265 1,10 
FA metabolism, IR CD36 molecule Cd36 0,012 1,36 0,999 1,00 0,014 1,36 
FA metabolism Acyl-CoA synthetase family member 2 Acsf2 0,038 1,28 0,022 -1,37 0,518 1,08 
TCA cycle, FA metabolism, IR Malonyl-CoA decarboxylase, mitochondrial Mlycd 0,024 1,23 0,208 -1,15 0,477 -1,08 
TCA cycle Isobutyryl-CoA dehydrogenase, mitochondrial Acad8 0,026 -1,21 0,002 -1,20 0,932 -1,01 
TCA cycle Pyruvate dehydrogenase (E1 component) beta Pdhb 0,004 -1,20 0,003 -1,36 0,144 1,13 
TCA cycle Pyruvate dehydrogenase (E1 component) alpha Pdha1 0,041 -1,17 0,009 -1,22 0,491 1,04 
TCA cycle Pyruvate dehydrogenase phosphatase regulatory subunit  Pdpr 0,008 -1,24 0,047 -1,13 0,106 -1,10 
TCA cycle Dihydrolipoamide S-acetyltransferase Dlat 0,003 -1,30 0,012 -1,28 0,814 -1,01 
TCA cycle Succinate dehydrogenase; flavoprotein subunit Sdha 0,022 -1,18 0,089 -1,14 0,649 -1,03 
TCA cycle Isocitrate dehydrogenase [NAD] subunit Idh3g 0,017 -1,42 0,001 -1,31 0,496 -1,08 
TCA cycle 2-oxoglutarate dehydrogenase, mitochondrial Ogdh 0,074 -1,17 0,041 -1,21 0,446 1,04 
 L-lactate dehydrogenase A Ldha 0,001 1,60 0,958 -1,01 <0,001 1,61 
Mitochondria, FA 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial Hibch 0,403 -1,06 0,018 -1,18 0,020 1,12 
Mitochondria 3-hydroxyisobutyrate dehydrogenase, mitochondrial Hibadh 0,738 1,04 0,036 -1,26 0,005 1,30 
Mitochondria Mitochondrial-processing peptidase subunit beta Pmpcb 0,049 -1,17 0,011 -1,36 0,142 1,16 
Mitochondria Mitochondrial import receptor subunit TOM22 Tomm22 0,299 1,16 0,006 -1,46 0,001 1,70 
Mitochondria Translocase of inner mitochondrial membrane 8  Timm8a1 0,015 1,80 0,613 1,09 0,004 1,65 
Mitochondria Mitochondrial Rho GTPase 1 Rhot1 0,008 3,11 0,862 1,01 0,010 3,08 
Mitochondria Translocase of outer mitochondrial membrane 70 Tomm70a 0,001 -1,41 0,118 -1,13 0,010 -1,25 
Mitochondria Mitochondrial import membrane translocase subunit Timm50 0,474 1,08 0,418 -1,08 0,010 1,17 
Mitochondria Mitochondrial import receptor subunit TOM40 homolog Tomm40 0,024 1,23 0,923 1,01 0,022 1,22 
Mitochondria Translation factor Guf1, mitochondrial Guf1 0,026 -4,87 0,022 -5,32 0,791 1,09 
Mitochondria Elongation factor G, mitochondrial Gfm1 0,011 -1,24 0,021 -1,20 0,422 -1,03 
Mitochondria Dynamin-like protein, mitochondrial Opa1 0,099 -1,16 0,069 -1,16 0,994 1,00 
Mitochondria, IR Cytochrome c oxidase subunit 6A2 Cox6a2 0,021 3,65 0,369 1,42 0,113 2,57 
Mitochondria Cytochrome c oxidase assembly factor 3 Coa3 0,007 - 0,934 1,03 0,002 - 
Mitochondria Mitochondrial transcription termination factor 2 Mterf2 0,045 -2,39 0,005 -2,27 0,821 -1,05 
Mitochondria ATP synthase F1 complex assembly factor 2 Atpaf2 0,249 1,33 0,106 -1,21 0,040 1,62 
Mitochondria ATP synthase subunit beta, mitochondrial Atp5b 0,145 1,22 0,277 -1,15 0,006 1,41 
Mitochondria BolA-like protein 3 Bola3 0,010 -2,77 0,025 -2,26 0,164 -1,22 
Mitochondria A-kinase anchor protein 1, mitochondrial Akap1 0,185 -1,19 0,057 -1,31 0,471 1,10 
Mitochondria Aldehyde dehydrogenase, mitochondrial Aldh2 0,013 -1,20 0,467 1,05 0,001 -1,26 
Mitochondria 3-oxoacyl-[acyl-carrier-protein] synthase, mitochondrial Oxsm 0,890 1,01 0,013 -1,20 0,037 1,22 
Mitochondria Elongation factor 1-delta Eef1d 0,011 1,22 0,065 1,17 0,529 1,04 
Mitochondria repiratory chain NADH dehydrogenase 1 beta subcomplex subunit 3 Ndufb3 0,221 1,33 0,840 -1,04 0,020 1,38 
Mitochondria repiratory chain NADH dehydrogenase 1 alpha subcomplex subunit 13 Ndufa13 0,288 1,22 0,611 -1,08 0,027 1,32 
Mitochondria repiratory chain NADH dehydrogenase 1 beta subcomplex subunit 10 Ndufb10 0,171 1,25 0,915 -1,01 0,006 1,27 
Mitochondria repiratory chain NADH dehydrogenase flavoprotein 2, mitochondrial Ndufv2 0,335 1,13 0,325 -1,12 0,008 1,27 
Mitochondria repiratory chain NADH dehydrogenase 1 alpha subcomplex subunit 11 Ndufa11 0,010 1,99 0,704 1,05 0,009 1,90 
Mitochondria repiratory chain NADH dehydrogenase 1 alpha subcomplex subunit 9 Ndufa9 0,160 1,28 0,876 1,02 0,038 1,25 
Mitochondria repiratory chain NADH dehydrogenase iron-sulfur protein 2 Ndufs2 0,391 -1,09 0,040 -1,26 0,031 1,16 
Energy metabolism Creatine kinase M-type Ckm 0,066 -1,24 0,032 -1,25 0,948 1,00 
Energy metabolism Nucleoside diphosphate kinase 3 Ndk3  0,640 -1,38 0,032 -2,65 0,030 1,92 
Energy metabolism NAD-dependent protein deacetylase sirtuin-3 Sirt3 0,297 -1,16 0,044 -1,47 0,196 1,27 
Energy metabolism NAD-dependent protein deacylase sirtuin-5 Sirt5 0,142 -1,17 0,033 -1,18 0,867 1,01 
Energy metabolism,  NAD-dependent protein deacetylase sirtuin-2 Sirt2 0,039 -1,63 0,033 -1,72 0,715 1,06 
Inflammation Macrophage migration inhibitory factor Mif 0,797 1,13 <0,001 -1,93 0,040 2,19 
Inflammation Interferon-inducible GTPase 1 Irga6 0,038 -3,04 0,275 -4,79 0,617 1,57 
Inflammation Serpin family F member 2 Serpinf2 0,025 1,58 0,915 1,02 0,011 1,55 
Inflammation Fibrinogen beta chain Fgb 0,032 1,48 0,361 -1,27 0,058 1,87 
Inflammation Mitogen-activated protein kinase kinase 1 Map2k1 0,011 -1,32 0,291 -1,14 0,107 -1,16 
Inflammation, hypertension Plasma kallikrein B1 Klkb1 0,033 2,10 0,311 1,30 0,073 1,62 
Inflammation, hypertension Kininogen1 Kng1 0,002 1,72 0,335 -1,13 0,0002 1,94 
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Inflammation, atherosclerosis Plasminogen Plg 0,008 1,60 0,521 1,09 0,010 1,47 
Inflammation, atherosclerosis Ras homolog family member A rho A 0,010 1,58 0,117 1,23 0,086 1,29 
Inflammation, atherosclerosis Fibronectin Fn1 0,007 1,55 0,252 1,16 0,038 1,33 
Inflammation, atherosclerosis, IR Signal transducer and activator of transcription 1 Stat1 0,031 -2,94 0,223 -3,00 0,969 1,02 
Atherosclerosis Intercellular adhesion molecule 1 Icam1 0,037 2,07 0,273 1,33 0,270 1,56 
Atherosclerosis Apolipoprotein A-IV Apoa4 0,013 1,62 0,212 1,24 0,106 1,31 
Atherosclerosis, infarction Glutathione S-transferase Mu 1 Gstm1 0,026 1,25 1,152 1,15 0,243 1,08 
Thrombosis, Heparin cofactor 2 Serpind1 0,033 2,68 0,621 1,11 0,028 2,42 
Thrombosis, endothelial cell apoptosis Antithrombin-III Serpinc1 0,014 1,56 0,167 1,21 0,052 1,29 
Hypertension, IR Adiponectin Adipoq 0,033 1,39 0,280 1,17 0,067 1,19 
Hypertension, infarction Solute carrier family 8 member A1 Slc8a1 0,004 -1,37 0,034 -1,29 0,550 -1,06 
Nitric oxyde Guanylate cyclase soluble subunit beta-1 Gucy1b3 0,002 -2,76 0,893 1,07 0,001 -2,94 
Oxidative stress Glutathione reductase, mitochondrial Gsr 0,005 1,23 0,066 1,13 0,153 1,09 
Endothelial cell dysfuntion, infarct Prostacyclin synthase Ptgis 0,038 3,08 0,020 3,69 0,789 -1,20 
Endothelial cell dysfuntion, infarct, IR Paraoxonase 1 Pon1 0,014 - 0,014 - - - 
Endothelial cell dysfuntion, infarct, IR Apolipoprotein A1 Apoa1 0,029 1,62 0,023 1,65 0,849 -1,02 
Endothelial cell dysfuntion, infarct Cathepsin D Ctsd <0,001 1,66 0,046 1,23 <0,001 1,35 
Endothelial cell apoptosis Ferritin heavy chain 1 Fth1 0,014 1,72 0,122 1,29 0,035 1,34 
Endothelial cell apoptosis Voltage-dependent anion channel 1 Vdac1 0,006 1,25 0,949 1,00 0,003 1,25 
Endothelial cell apoptosis Catenin beta-1 Ctnnb1 0,017 -1,19 0,156 -1,11 0,351 -1,07 
Endothelial cell apoptosis Transferrin receptor protein 1 Tfrc 0,048 -1,38 0,007 -1,63 0,199 1,18 
Endothelial cell apoptosis Xanthine dehydrogenase Xdh 0,011 -1,47 0,635 1,08 <0,001 -1,58 
Cardiac function Popeye domain-containing protein 2 Popdc2 0,032 5,43 0,965 -1,02 0,014 5,52 
Cellular hometostasis ATPase Na+/K+ transporting beta 3 Atp1b3 0,010 1,92 0,020 1,53 0,325 1,26 
Cellular hometostasis ATPase Na+/K+ transporting alpha 2 Atp1a2 0,017 -1,24 0,667 1,04 0,012 -1,29 
Cellular hometostasis Chloride intracellular channel 4 Clic4 0,017 -1,27 0,886 1,01 <0,001 -1,28 
Cellular hometostasis Calcium/calmodulin-dependent protein kinase type II Camk2d 0,001 -1,41 0,341 -1,08 0,001 -1,30 
Cellular hometostasis Ferritin light chain 1 & 2 Ftl1;Ftl2 0,019 1,37 0,031 1,36 0,919 1,01 
Cellular hometostasis Metalloreductase STEAP4 Steap4 0,705 -1,19 0,024 6,71 0,036 -7,99 
Cellular morphology Filamin-B Flnb 0,269 1,13 0,068 -1,23 0,001 1,38 
Cellular morphology Myosin-7 Myh7 0,306 1,38 0,027 -5,19 0,020 7,15 
Cellular morphology Myosin-Ic Myo1c 0,461 -1,06 0,066 1,22 <0,001 -1,29 
Cellular morphology Capping actin protein of muscle Z-line beta Capzb 0,025 -1,18 0,212 1,09 <0,001 -1,29 
Cellular morphology Actin, alpha skeletal muscle Acta1 0,107 -1,90 0,029 -3,87 0,128 2,04 
Cellular morphology Myosin-XVIIIa Myo18a 0,014 -1,26 <0,001 -1,22 0,620 -1,03 
Cellular morphology Titin Ttn 0,014 -1,37 0,016 -1,15 0,099 -1,20 
Cellular morphology Myocardial zonula adherens protein Myzap 0,001 -1,33 0,004 -1,26 0,286 -1,05 
Cellular morphology Myomesin-2 Myom2 0,019 -1,17 0,045 -1,17 0,981 -1,00 
Cellular morphology Actin-related protein 2/3 complex subunit 2 Arpc2 0,752 1,04 0,037 1,35 0,003 -1,30 
Cellular morphology Valine--tRNA ligase Vars 0,151 -1,13 0,108 1,16 <0,001 -1,32 
Cellular morphology GTP-binding nuclear protein Ran Ran 0,010 1,41 0,009 1,42 0,925 -1,01 
Endothelin downstream signaling Phospholipase C Plcb4 - - 0,009 2,08 - - 
Endothelin downstream signaling Mapk1; Erk2  0,343 1,25 0,103 1,53 0,330 1,22 
 Afamin Afm <0,001 5,15 0,064 1,40 0,001 3,67 
 Flavin adenine dinucleotide synthetase 1 Flad1 0,010 -1,62 0,005 -1,38 0,249 -1,17 
 Musashi RNA binding protein 2 Msi2 0,022 -1,29 0,011 -1,49 0,298 1,15 
 Pre-mRNA-processing factor 19 Prpf19 0,046 -1,35 0,298 -1,22 0,480 -1,10 
 Adenylosuccinate lyase Adsl 0,031 -1,31 0,017 -1,41 0,584 1,08 
  Vinculin Vcl 0,005 1,15 0,002 1,13 0,600 1,02 
Results from Label-free protein quantification showing the ratios of protein expression levels in sunitinib versus vehicle, sunitinib versus sunitinib+macitentan and sunitinib+macitentan 
versus vehicle. Numbers indicate the fold change (FC) between two groups and the p-value of the two tailed Student t.test Data are expressed as Fold change (FC). The sign “–“ indicates 
undetected protein in the denominator group. n=6 for each. ATP: Adenosine triphosphate; CD36: cluster of differentiation 36; FA: fatty acid; GTP: Guanosine-5'-triphosphate; IR: insulin 
resitance; K+: potassium; Na+: sodium; NAD: nicotinamide adenine dinucleotide; RAB: Ras-related protein; RNA: Ribonucleic acid; TCA: tricarboxylic acid. 
 
Macitentan reduces cardiac fibrosis and 
downregulates myocardial ETA receptors 
We studied the effect of sunitinib, with or 
without the addition of macitentan, on cardiac 
fibrosis. Sunitinib treatment was associated with the 
development of cardiac fibrosis that was prevented by 
co-administration of macitentan (Figure 6B). Since the 
ETA receptor is known to mediate fibrosis (33) and 
cardiac hypertrophy (34), it can be assumed that 
sunitinib-induced cardiac injuries are mediated 
through the ETA receptor. We further explored the 
effects of macitentan on the ET pathway in order to 
define which receptor is involved in 
sunitinib-induced cardiac injuries. Macitentan did not 
affect ET-1 or ETB receptor expression, but 
significantly downregulated myocardial ETA receptor 
expression (Figure 6A). 
Moreover, both ETA and ETB receptors of the 
aorta were increased in mice treated with sunitinib 
and sunitinib+macitentan (Figure S1). Since elevated 
ET-1 is found in patients and rodents treated with 
sunitinib (21) and elevated ET receptors characterizes 
hypertension (35), we speculated that the ET pathway 
was activated by sunitinib. Accordingly, the ET 
downstream signaling, phospholipase C, protein 
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kinase C and MAPK1;ERK2, was high in all samples 
(n=6) of sunitinib-treated hearts but was undetectable 
in the vehicle group. In addition, these effectors were 
detected only in 3 samples out of 6 (50%) in the 
sunitinib+macitentan group and were expressed at 
lower level than the sunitinib-group. 
Macitentan reverses the sunitinib-induced 
aerobic to anaerobic switch  
Label-free pan-analysis of protein expression in 
mouse hearts collected from the three groups (vehicle, 
sunitinib and sunitinib+macitentan) is shown in 
Table 2. Data analysis using Ingenuity® and Pathway 
Studio® softwares showed that sunitinib induced an 
impairment in carbohydrate and fatty acid oxidative 
metabolisms and in the TCA cycle. Mitochondrial 
homeostasis was also deregulated, as shown by 
reduced expression in both the inner and outer 
mitochondrial membrane complexes, in 
mitochondrial transporters and in mitochondrial 
translation factors. In line with the effect of sunitinib 
on myocardial flux dysfunction. Several patterns of 
protein clusters were drastically different in the 
sunitinib and vehicle groups (Figure 7C). Protein 
clusters involved in myocardial infarction, endothelial 
cell dysfunction and apoptosis, atherosclerosis, 
thrombosis, inflammation and hypertension, were 
targeted by sunitinib. Comparing protein expression 
in the sunitinib-treated group with that in the vehicle 
and sunitinib plus macitentan groups highlighted 
once again the protective effects of macitentan, 
notably on the following clusters: myocardial 
infarction, endothelial cell dysfunction and apoptosis 
(Figure 7A), glycogen metabolism, TCA cycle, acetyl 
CoA biosynthesis. The level of expression of the 
pyruvate dehydrogenase (PDH) components (alpha 
and beta E1 components of the complex, PDH 
phosphatase) were maintained at control levels by 
macitentan in the oxidative phosphorylation deficient 
myocardium induced by sunitinib (Figure 7B). 
Interestingly, the levels of expression of some proteins 
involved in glycolysis were augmented by 3 weeks of 
sunitinib treatment (e.g. glucose-6-phosphate 
isomerase and phosphoglycerate mutase), while those 
of others were reduced, e.g. muscle-type 
phosphofructokinase and glyceraldehyde-3- 
phosphate dehydrogenase. Sunitinib-treated hearts 
showed higher lactate dehydrogenase (LDH) that is 
released during tissue hypoxia and damage. 
Surprisingly, sunitinib induced a dramatic (8-fold) 
increase in the expression of GLUT4 (SLC2a4), the 
insulin-regulated transporter of glucose at the plasma 
membrane. However, the level of Rab10, a small 
ras-family GTPase required for translocation of 
GLUT4, was significantly decreased. Together with a 
trend for elevated blood sugar in the sunitinib treated 
group (190±38 mg/dL), these results were coherent 
with an insulin-resistant type of diabetic metabolic 
profile of the sunitinib treated hearts. Addition of 
macitentan to sunitinib suppressed the diabetic-like 
clusters (Figure 7C), returned glycaemia to 
pre-treatment levels (171±17 mg/dL and 173±23 
mg/dL in the vehicle and sunitinib+macitentan 
treated groups, respectively), and activated clusters 
for glycolysis. Macitentan only partially reverted the 
effects of sunitinib on the level of GLUT4 and Rab10, 
but significantly increased the level of expression of 
the pleiotropic regulatory protein sirtuin 2, in line 
with the role of this protein in energetic metabolism 
preservation.  
Discussion  
Sunitinib treatment is limited by its 
cardiovascular side effects. A recent study reported 
that sunitinib induces an early switch of cardiac 
metabolism to anaerobic glycolysis and impairs heart 
function (30). Here, we show that in addition to this 
metabolic switch, myocardial remodeling by sunitinib 
also induces a reduced glucose uptake resembling the 
one found during insulin resistance, and show that 
sunitinib cardiotoxicity is a combination of several 
complex mechanisms occurring over a sequential time 
course. Moreover, we show that sunitinib-induced 
cardiac injury and dysfunction are prevented through 
inhibition of endothelin signaling, strongly 
supporting a role for this pathway in sunitinib’s 
cardiotoxic effects (Figure 8). 
Our results confirm that FDG-PET is able to 
quantify the metabolic changes induced by sunitinib 
administration. It remains unclear why this has not 
been noted previously given the widespread use of 
FDG-PET in the staging and follow-up of cancer 
patients. One explanation might be that myocardial 
glucose metabolism is a complex, tightly regulated 
mechanism that varies according to nutrient and 
oxygen levels. Under physiological conditions, the 
heart preferentially uses oxidization of fatty acids as 
fuel and switches to glycolysis in high glucose and 
insulin or low oxygen conditions by activating 
synthesis and translocation to the plasma membrane 
of the glucose transporter GLUT4 (36). Therefore, 
myocardial FDG uptake varies according to fasting 
status, diet, diabetes and ischemia (37). In mouse and 
man, FDG uptake is higher in non-fasting than in 
fasting conditions (37) and in oncology studies FDG 
PET imaging is acquired under fasting conditions in 
order to minimize muscular and myocardial uptake 
and improve tumor detection. In contrast, cardiac 
PET-FDG often utilizes an euglycemic clamp (glucose 
load with additional insulin administration after 
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overnight fasting) in order to maximize heart uptake 
(37, 38). Interestingly, in the case of vascular 
dysfunction, PET images of the heart look different 
under fasting and non-fasting conditions: ischemic 
territories appear as hot spots with higher FDG 
uptake than the intact myocardium after fasting (39) 
while they may not differentiate from intact tissue in 
non-fasted conditions after a glucose load (40–42). In 
the absence of sunitinib treatment, FDG-SUV and 
metabolic flux were lower in fasted than in non-fasted 
states. We show here that the increase in FDG uptake 
after one week of sunitinib was more pronounced in 
fasted than in non-fasted mice. Therefore, dietary 
status also influences the FDG cardiac uptake under 
sunitinib treatment.  
Systemic administration of sunitinib rapidly 
induces a metabolic switch towards glycolysis with 
reduced expressions of key enzymes of the TCA cycle 
and key proteins for mitochondrial oxidative 
phosphorylation (OXPHOS) and for the 
beta-oxidation of fatty acids. We observed this switch 
regardless of whether the animals were fasted or not 
(although with a different intensity in both 
conditions) at one and 3 weeks after beginning of the 
anti-angiogenic treatment. O’Farrel et al. also showed 
increased FDG uptake as early 2-3 days after 
introduction of sunitinib in mice and 5 days in rats 
(30). Overall, the sunitinib-treated heart tends to 
switch towards an anaerobic glycolysis metabolism 
with accumulation of lactate, similar to the one found 
in hypoxic muscles and during heart failure (43). At 
the proteomic level, the changes in the expression of 
proteins involved in metabolic pathways in the hearts 
of non-fasted animals treated during one and three 
weeks were largely consistent. For instance, 3 weeks 
of treatment decreased the PDH complex and 
increased levels of LDH, confirming the glycolytic 
switch combining inhibition of the pathways leading 
to acetyl CoA biosynthesis and diversion toward 
anaerobic conversion of pyruvate to lactate. 
Sunitinib-treated hearts were also unlikely to use 
glycogen as energy source since they expressed very 
low phosphorylase B kinase, in agreement with the 
elevated glycogen level described by Rees et al. (32). 
Interestingly, the mechanism of sunitinib’s cardiac 
toxicity is not due to a reduction in blood vessel 
density in the myocardium. This is different from the 
action on tumor vessels, whose number is drastically 
reduced after a short course of sunitinib (44).  
 
 
Figure 5. Macitentan prevents myocardial flux dysfunction induced by sunitinib. (A) Difference treatment – baseline of myocardial metabolic flux and metabolic rate 
of glucose (MRglu) for vehicle (n=5), sunitinib (n=5) and sunitinib+macitentan (n=6) groups. Data are expressed as mean ± SEM, *p <0.05 compared to baseline, $p <0.05 
compared to other at week 3. #p <0.05 compared to sunitinib group at week 3. (B) Micrographs of cardiac sections of microvascular staining (lectin in green and nuclei in blue) 
at D22 in non-fasted C57Bl/6 mice. (C) Quantification of vessels area reported on number of cells for vehicle (n=9), sunitinib (n=9) and sunitinib+macitentan (n=7) groups at D22 
in non-fasted C57Bl/6 mice. MRGlu: metabolic rate of glucose.  
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Figure 6. Protective effects of macitentan involve ET receptors: (A) ng of ET-1, ETA and ETB receptor mRNA reported on ng of 18s RNA in the myocardium (n=6 for 
each). (B) Micrographs of cardiac sections of fibrosis marker (Picrosirius red) at D22 non-fasted C57Bl/6 mice. (C) Quantification of fibrosis for vehicle (n=9), sunitinib (n=9) and 
sunitinib+ macitentan (n=7) groups at D22 in non-fasted C57Bl/6 mice. Data are expressed as mean ± SEM, $p <0.05; $$$p <0.001 compared to other. EDN1: Preproendothelin-1; 
EDNRA: endothelin receptor type A; EDNRB: endothelin receptor type B. 
 
Figure 7. Cardioprotective effects of macitentan. (A) Pathway studio representations of proteins involved in myocardial infarction and endothelial cell apoptosis showing 
the changes in protein expression levels in the myocardium of the sunitinib group and the (vehicle and sunitinib+macitentan) groups. Red indicates significantly (p<0.05) 
upregulated proteins, blue significantly (p<0.05) down-regulated proteins. (B) Ingenuity representation of the changes in Pyruvate dehydrogenase complex expression in the 
myocardium of the sunitinib group in comparison to the (vehicle and sunitinib+macitentan) groups. Green shows significantly (p<0.05) downregulated proteins in the sunitinib 
group. (C) Table of the diabetes-related pathways most significantly perturbed by sunitinib in mouse myocardium and correction by macitentan. n=6 for each group. n.s: 
non-significant. Proteins described in Table 2. 
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Figure 8. Schematic representation of the mechanism of sunitinib-induced cardiac side effects: (A) Sunitinib upregulates glycolysis and downregulates oxidative 
metabolism in cardiac mitochondria. (B) Sunitinib induces resistance to insulin stimulation of cardiac glucose uptake. The metabolic switch is an immediate early response to 
sunitinib while insulin resistance either appears later or is masked by the metabolic switch during the early stages of sunitinib treatment. Both mechanisms depend on signaling 
by the endothelin pathway, and lead to myocardial fibrosis and impaired cardiac function, and are reversed by the endothelin receptors antagonist macitentan. Red indicates 
upregulated proteins and pathways, blue indicates downregulated protein and pathways. ATP: Adenosine triphosphate; ET-1: endothelin 1; ETA: endothelin receptor type A; FA: 
fatty acid; GLUT: glucose transporter protein; O2: oxygen; OXPHOS: oxidative phosphorylation; TCA: tricarboxylic acid. 
 
Here, macitentan treatment prevented the 
deficiency in acetyl CoA biosynthesis and impairment 
of the TCA cycle and suppressed the protein patterns 
typical of endothelial cell apoptosis and myocardial 
infarction. Others have shown that macitentan also 
prevented the hypertension associated with sunitinib 
(25). Our results suggest that the cardiotoxic effects of 
sunitinib are mediated by the ETA receptor. The 
current explanation for the cardiac toxicity of 
sunitinib is a direct toxicity on the myocardium with 
mitochondrial dysfunction, that is exacerbated by 
hypertension since cardiomyocytes use glucose as 
main energy source when subjected to pressure 
overload (45). Reduced availability of oxygen in the 
myocardium will also lead to rapid metabolic changes 
with increased FDG uptake. This is the case in the 
hearts of fasted mice at one day after transverse aortic 
constriction surgery (46). Moreover, during fasting 
the ischemic territories of the heart show a higher 
FDG uptake than healthy myocardium that prefers 
fatty acids as energy substrate (47). The present data 
support a role for the endothelin system in mediating 
switch towards anaerobic metabolism. 
We observed a decreased metabolic flux in the 
hearts of mice treated with sunitinib for 3 weeks. 
Although they did not elaborate on this result, 
O’Farrell et al. observed the same trend and showed a 
similar metabolic rate of glucose at 3 weeks of 
treatment in sham and sunitinib treated animals (30). 
Interestingly, in their study, as in ours, the apparent 
reversal of the early metabolic switch induced by 
sunitinib was not accompanied by an improvement in 
the left ventricular ejection fraction. This delayed 
effect of sunitinib may be in line with a case report 
describing decreased myocardial FDG uptake in 
patients treated with imatinib plus sorafenib who 
later developed a cardiac event (48). Therefore, we 
explored the possible mechanisms underlying this 
observation. On the one hand, sunitinib-treated hearts 
presented anaerobic metabolism and it is known that 
PDH inhibition leads to a slow recovery of glucose 
uptake and uncoupling of glycolysis (49), and that 
lactate accumulation decreases glucose uptake (43). 
On the other hand, patterns of protein expression in 
the 3-week sunitinib-treated heart resembled the one 
seen in diabetic patients in which the FDG metabolic 
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flux is reduced (50), as well as the pattern in diabetic 
rats where myocardial glucose uptake is reduced 
under ischemic conditions (51). Despite the lower 
metabolic rate of glucose in sunitinib-treated hearts, 
we observed a dramatic increase of GLUT4 activated 
in high glycaemia-high insulinemia conditions (36). 
However, the expression of Rab10, that controls the 
plasma membrane insertion of GLUT4 and whose 
activation is under control of the AS160 GTPase, a 
substrate of AMPK which is known to be inhibited by 
sunitinib (22), was reduced. Therefore, it is likely that 
although overexpressed in 3-week sunitinib treated 
hearts, GLUT4 was not inserted in the plasma 
membrane and not actively transporting glucose or 
FDG inside the cardiomyocytes.  
Overall our results indicate that, in mice, a 
3-week sunitinib course (the regimen is usually 4 
weeks in patients) induces a form of cardiac insulin 
resistance. This is not totally surprising as sunitinib 
and TKI are known to affect glucose levels to the point 
that they have been considered as potential drugs for 
type 2 diabetes (52). In our study, the addition of 
macitentan largely improved the metabolic rate of 
glucose and suppressed the sunitinib-induced insulin 
resistance and diabetic patterns. Moreover, ETA 
activation is associated with impaired glucose uptake 
via the inhibition of the AMPK/Akt signaling 
pathway of the translocation of GLUT4 in skeletal 
muscle (53). Here, we demonstrate that the 
sunitinib-induced reduction in glucose uptake after 
prolonged treatment is mediated by the ETA receptor 
through the inhibition of insulin-stimulated AMPK. 
Other studies have shown that disruption of the 
endothelin pathway is associated with impaired 
glucose uptake in skeletal muscle. Shemyakin et al. 
showed decreased insulin-stimulated Akt 
phosphorylation by ET-1, and infusion of ET-1 
reduced insulin sensitivity in humans and in animals 
(54,55). In addition, ET-1 blockade by 
ETA/ETB receptors inhibition increases glucose 
uptake in patients with insulin resistance (54, 55).  
Our results suggest that two mechanisms are at 
work in the cardiotoxic effects of sunitinib: (i) in the 
first days after initiation of treatment, a metabolic 
switch towards glycolysis with increased FDG uptake 
and, (ii) evidenced after at least 3 weeks of treatment, 
a type of insulin resistance that leads to subnormal 
FDG uptake. Our present data show that the 
cardiotoxicity of sunitinib is for a good part related to 
a deregulation of cardiac metabolism, which in some 
respect is similar to the one observed in other 
situations. It has been demonstrated that during 
ischemia, the heart is not able to use its metabolic 
reserve (56) and is associated with lactate acidosis 
leading to contractile dysfunction (57). Similarly, 
hypertrophic hearts are not able to increase glucose 
uptake enough to sustain the energy demand (58), 
and by-products from glycolysis and glycogen 
utilization are required for proper myocardium 
relaxation (59). This metabolic dead end is 
concomitant with major deleterious consequences on 
three key components of cardiac physiology: (i) 
mitochondrial homeostasis; (ii); fibrosis and (iii) 
contractile function. Fibrosis is responsible for 
impaired myocardial relaxation and we show here 
that impaired cardiac output was due to a decreased 
left ventricular volume during the diastole (LVID,d), 
responsible for diastolic dysfunction (60, 61). This has 
functional consequences with decreased flow 
velocities, leading to cardiac dysfunction.  
The therapeutic perspective is to control and, 
whenever possible, to prevent the cardiotoxicity of 
anticancer drugs. Regarding sunitinib, our results 
show that the administration of macitentan reverts 
most, if not all, the effects of sunitinib on cardiac 
metabolism and prevents impairment of left 
ventricular function and fibrosis. Macitentan is a 
mixed ETA/ETB antagonist approved for the 
treatment of pulmonary arterial hypertension and has 
no known direct or indirect interaction with sunitinib 
of other TKI (FDA). Furthermore, non-selective ET 
receptors antagonism prevents hypertension and 
renal injury (24) induced by sunitinib. In the future, it 
will be interesting to test if the use of a selective ETA 
receptor antagonism produces comparable 
cardioprotection since ET-1 is known to exert a 
pro-fibrotic action (62) and hypertrophy (34) via the 
ETA receptor.  
We have shown here that co-administration of 
macitentan prevents deregulation of myocardial 
metabolism and cardiac fibrosis and restores the 
diastolic function impaired by sunitinib. Taken 
together, these results support the administration of a 
mixed ETA/ETB inhibitor such as macitentan to 
protect the myocardium during sunitinib treatment. 
Our pre-clinical results call for clinical imaging 
studies aiming to identify the risk of developing side 
effects at an early stage of sunitinib treatment, and 
consequently to administer preventive therapy (22). 
Because of its clinical importance, further exploration 
of the capacity of macitentan therapy to protect the 
heart from sunitinib-induced cardiac dysfunction is 
worth exploring in a theranostic approach. 
Materials and Methods 
Experimental design 
Animal experiments were authorized by the 
French Ethical committee for animal experimentation 
under No. 15-045 and performed by certified personal 
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following the French law of animal welfare on animal 
experimentation n°2013-118. Female nude (nu/nu) 
and C57BL/6 mice (Janvier Labs, France) 15 weeks 
aged were maintained in controlled temperature 
(24°C) and relative humidity (50%) on a 
12/12-light/dark cycle and were fed ad libitum. 
Sunitinib malate (Sutent®, Pfizer, USA) was dissolved 
at 10mg/mL in DMSO/PBS (1:4). 40 mg/kg/ml is the 
minimum dosage that permit to demonstrate 
anti-tumor effect and produce comparable plasma 
concentrations to those found in patients (8,63,64). 
However, preliminary results in our institution 
demonstrated the variability in the results with this 
dosage. Based on that, we administered sunitinib 
daily by oral gavage in a dose of 50 mg/kg body 
weight to improve homogeneity and reduce number 
of animals. In the sunitnib+macitentan group, 
macitentan (20mg/mL) was added to the gavage 
solution, with the volume maintained at 150µL.  
This study followed a standard protocol for 
monitoring of short-term response to therapy in 
fasted tumor-bearing nude mice. Mice were injected 
bilaterally in the left and right flanks subcutaneously 
with 1 x 107 Cricetulus griseus (CCL-39) tumor cells 
suspended in 300µl of culture medium. The PET scan 
was performed before and 2 days after a 5-day course 
of 50mg/kg sunitinib malate (treatment group) or 
vehicle (vehicle group) (Figure 1A). To check whether 
the increased SUV was independent of the presence of 
a tumor in immunodeficient animals, the same 
protocol was reproduced in C57BL/6 
immunocompetent mice fasted before the PET 
examination. Chow diet was removed the day before 
the experiment for a 12 hours fasting. Cardiac 
echography was also performed to measure heart 
function (Figure 1B). Finally, to explore the 
pathophysiological mechanisms of sunitinib 
cardiotoxicity, PET-FDG and echocardiography were 
performed in non-fasted mice at baseline and 1 and 3 
weeks of a three-week course of sunitinib or vehicle. 
A third group with co-administration of sunitinib and 
the endothelin receptor antagonist macitentan was 
added to test the hypothesis that the cardiac effects of 
sunitinib were, in part, mediated by the endothelin 
pathway (Figure 1C). For all the panels, animals of 
both groups were randomly assessed, experiment and 
analysis were realized blinded and animals from both 
groups were image the same day. 
Cardiac Positron Emission Tomography (PET) 
All mice from groups A and B were fasted 
overnight. Mice from panel C were not fasted and had 
free access to food and water. Mice were anesthetized 
(2±0.5% isoflurane in air), weighted and glycemia was 
measured in blood drawn from the caudal ventral 
artery using an Accu-Chek® Aviva Nano A 
(Accu-Chek, France). A catheter home-made from a 
26G needle (Fischer Scientific, France) connected to a 
5cm polyethylene tubing (Tygon Microbore Tubing, 
0.010" x 0.030"OD; Fisher Scientific, France) was 
inserted in the caudal vein for radiotracer injection. 
Mice were then installed into the PET-CT dedicated 
bed and respiration and body temperature were 
registered. Body temperature was maintained at 37°C 
and anesthesia was controlled on the breathing rate 
throughout the entire examination. CT was acquired 
in a PET-CT scanner (nanoScan PET-CT; Mediso, 
Hungary) using the following acquisition parameters: 
semi-circular mode, 39kV tension, 720 projections full 
scan, 300ms per projection, binning 1:4. Then, PET 
acquisition was started and, 30 seconds later, 10MBq 
of 2'-deoxy-2'-[18F]fluoro-D-glucose (FDG; Advanced 
Applied Applications, France) in 0.2mL saline was 
injected via the catheter. The first scan was a dynamic 
acquisition of 30.5min and was followed by a gated 
cardiac scan of 30min duration. PET data were 
collected in list mode and binned using a 5ns time 
window, with a 400-600keV energy window and a 1:5 
coincidence mode. Data were reconstructed using the 
Tera-Tomo reconstruction engine (3D-OSEM based 
manufactured customized algorithm) with 
expectation maximization iterations, scatter and 
attenuation correction. The first scan was 
reconstructed starting 10s before FDG injection with 
the following time sequence: 26 x 5s; 6 x 30s; 5 x 120s; 
3 x 300s and 3 x 600s. The second scan reconstructed 
in a single time frame from 45 to 60min post-injection. 
FDG accumulation was quantified as mean 
Standard Uptake Value (SUV, ratio of the 
radioactivity concentration in myocardium on the 
whole body concentration of the injected 
radioactivity) between 45 and 60min post-injection in 
3D volumes-of-interest (VOI) delineated 
semi-automatically by iso-contours at 45% threshold 
of maximal value in the myocardium on PET/CT 
fusion slices using the PMOD software package 
(PMOD Technologies Ltd, Zürich, Switzerland). 
Metabolic flux was quantified using compartmental 
modeling tool of PMOD software using the same VOI 
as above and a VOI semi-automatically delineated on 
the vena cava for the arterial input function as 
previously described (65). Metabolic rate of glucose 
were calculated by the multiplication of the metabolic 
flux by [plasma glucose (mmol/l)/lumped constant 
(fixed at 0.69)]. 
Echocardiography 
Conventional echocardiography was performed 
in anesthetized mice using a Vevo 2100 high 
resolution ultrasound device (Visualsonics, Toronto, 
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Canada) with a 40MHz probe (MS-550). Mice were 
anesthetized with 3% isoflurane in air for induction 
and maintained with 1.5%. Mice were depilated in the 
thoracic region and then placed in the supine position 
on a dedicated heating platform, allowing monitoring 
of ECG, temperature and respiratory frequency. All 
acquisitions were performed within body 
temperature limits 36-37.5°C. Parasternal long axis 
views were recorded and 3 consecutive 
measurements in M-mode were drawn to determine 
Left Ventricular Internal Diameter (LVID) at diastole 
(d) and systole (s) and Left Ventricular Posterior Wall 
thickness (LVPW) in both telediastole (d) and 
telesystole (s). Cardiac Output (CO) and the 
percentage of fractional shortering (FS) were then 
calculated using the VevoLab Software (Visualsonics). 
Mitral flow deceleration time was calculated from 
mitral flow velocities using Pulsed Wave Doppler 
(PW Doppler). Ascending aorta diameter (Ao) and 
Left Atrium diameter (LA) were measured using 
M-mode in parasternal long axis. Aortic velocity 
tracking integral (AoVTI) was measured using PW 
Doppler, in suprasternal view allowing measurement 
of mean aortic velocity and peak aortic velocity. 
Assessment of microvascular density 
Cardiac microvessels were stained using 
Isolectine B4 Griffonia Simplicifolia-FITC (Sigma 
Aldrich). Nuclei were counter stained with DAPI. 
Microvessels and nuclei were counted in 4 fields at a 
magnification of x200 in 2 independent sections from 
each heart using Matlab® based software. Microvessel 
density was normalized to the number of nuclei. 
Assessment of cardiac fibrosis 
Frozen sections were incubated with Picrosirius 
red (VWR) 0.1% in picric acid (Sigma) in a Leica 
ST5020 automatic stainer during 30min and 
dehydrated in ethanol and xylene. Whole sections 
were observed at a magnification of x20 using a 
Nanozoomer HT 2.0 (Hamamatsu) and fibrosis was 
quantified using Matlab® based software. 
Western blotting 
Twenty micrograms of each heart lysate were 
loaded onto a 10% SDS-PAGE gels (mini-protean TGX 
gels, BioRad) and transferred to nitrocellulose 
membranes. The membranes were blocked and 
immunoblotted with the following primary 
antibodies: GLUT1 (1:1000, ab652, Abcam), PGC1α 
(1:1000, ab54481, Abcam) and hexokinase II (1:500, 
bs-3993R, Interchim). Membranes were then 
incubated with horseradish peroxidase 
(HRP)-conjugated anti-rabbit secondary antibodies 
(1:10000, 474-1506, KPL). Chemiluminescence 
detection was performed using the ECL kit (Clarity 
Western ECl substrate; BioRad). Quantitation of 
immunoblots was done on digitalized images using 
ImageJ software. The intensity of immunoreactive 
bands was normalized by the loading control 
(Cyclophilin B, 1:1000, ab16045, Abcam). 
Proteomics 
Tissue sample preparation 
Frozen mouse hearts were individually ground 
under liquid nitrogen to yield a fine powder using a 
pestle and mortar. The tissue powder was weighted 
and solubilized in lysis buffer (4% SDS, 100mM 
Tris-HCl, pH 8.0). Protein extracts were clarified by 
centrifugation at 21,000×G, 1 hour, 4°C. Protein 
concentration of the supernatant was determined 
using bicinchoninic acid assay (BCA, Pierce). Peptides 
were prepared by Filter Aided Separation method 
(FASP) essentially as described (66). Briefly, 50µg of 
proteins from whole lysates were diluted to 100µL in 
solubilization buffer (50 mM Tris/HCl, pH8.5, SDS 
2%, 20mM TCEP, 50 mM chloroacetamide) and 
heated for 5 min at 95°C. After cooling to room 
temperature, extracts were diluted with 300µL Tris 
Urea buffer (Urea 8M, Tris/HCl 50mM (pH 8.5) and 
transferred onto 30kDa centrifuged filters and 
prepared for digestion as described (66). Proteins 
were digested during 14h at 37°C with µg trypsin 
(Promega) and peptides were desalted on C18 
StageTips (67). After drying, peptides were 
solubilized in 2% trifluoroacetic acid (TFA) and 
fractionated by strong cationic exchange (SCX) 
StageTips, mainly as described (68) except that 
fractions 1 and 2 were pooled in most experiments.  
Mass spectrometry analysis 
Mass spectrometry analyses were performed on 
a Dionex U3000 RSLC nano-LC- system coupled to a 
Q-Exactive mass spectrometer (Thermo Fisher 
Scientific). After drying, peptides from SCX StageTip 
fractions were solubilized in 10 µL of 0.1% TFA 
containing 2% acetonitrile (ACN). One µL was loaded, 
concentrated and washed for 3min on a C18 reverse 
phase precolumn (3µm particle size, 100 Å pore size, 
75 µm inner diameter, 2 cm length, Dionex, Thermo 
Fisher Scientific). Peptides were separated on a C18 
reverse phase resin (2 µm particle size, 100Å pore size, 
75µm inner diameter, 25cm length from Dionex) with 
a 3-hour gradient starting from 99% of solvent A 
containing 0.1% formic acid in H2O and ending in 40% 
of solvent B containing 80% acetonitrile, 0.085% 
formic acid in H2O. The mass spectrometer acquired 
data throughout the elution process and operated in a 
data-dependent scheme with full MS scans acquired 
with the Orbitrap, followed by up to 10 MS/MS HCD 
fragmentations in the Q-Exactive (Thermo Fisher) on 
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the most abundant ions detected. Settings were 
essentially as in (69) with slight modifications: the 
recurrent loop of the 10 most intense nLC-eluting 
peptides were HCD-fragmented between each full 
scan (data dependent mode). Resolution was set to 
70,000 for full scans at AGC target 1,10e6 within 60ms 
MIIT. The MS scans spanned from 350 to 1500m/z. 
Precursor selection window was set at 2Th, and 
MS/MS scan resolution was set at 17,500 with AGC 
target 1,10e5 within 60ms MIIT. HCD Normalized 
Collision Energy (NCE) was set at 27%. Dynamic 
exclusion was set to 30s duration. Spectra were 
recorded in profile mode. The mass spectrometry data 
were analyzed using Maxquant version 1,5,2,8 (70). 
The database used was a concatenation of human 
sequences from the Uniprot-Swissprot database 
(Uniprot, release 2015-02) and a list of contaminant 
sequences from Maxquant. The enzyme specificity 
was trypsin. The precursor mass tolerance was set to 
4.5ppm and the fragment mass tolerance to 20ppm for 
Q-Exactive data. Carbamidomethylation of cysteins 
was set as constant modification and acetylation of 
protein N-terminus and oxidation of methionines 
were set as variable modification. Second peptide 
search was allowed and minimal length of peptides 
was set at 7 amino acids. False discovery rate (FDR) 
was kept below 1% on both peptides and proteins. 
Label-free protein quantification (LFQ) was done 
using both unique and razor peptides. At least 2 such 
peptides were required for LFQ. The “match between 
runs” (MBR) option was allowed with a match time 
0.7 min window and an alignment time window of 
20min. For analysis, LFQ results from MaxQuant were 
imported into the Perseus software (version 1.5.1.6). 
Reverse and contaminant proteins were excluded 
from analysis. Contaminating proteins from culture 
medium, essentially coming from added serum, such 
as immunoglobulins or transferrin were also removed 
from the protein list. Protein copy numbers per cell 
were then calculated using the “Protein ruler” plugin 
of Perseus by standardization on total histone MS 
signal as described (71).  
Modeling with Ingenuity® and Pathway 
Studio® 
We used ingenuity pathway analysis (Ingenuity 
Systems, Redwood City, CA) and Pathway Studio 
(https://www.pathwaystudio.com/) to study 
pathways deregulated by sunitinib as already 
described (72). For both, data from proteomic were 
classified according to the fold change and p-value 
compared to reference group (i.e: vehicle) using a 
paired t.test and only significant deregulated proteins 
were enter in the software. Briefly, these software 
create hypothetical networks (including several 
proteins) to highlight networks that are significantly 
(p <0.05) different compared to a reference group (i.e: 
vehicle group or sunitinib + macitentan group). Those 
networks were assigned to a biological function(s), 
pathway(s) and/or disease(s) using the Ingenuity 
Pathways Knowledge Base, Pathway Studio database 
and the scientific literature. 
RNA extraction and qPCR 
RNA from hearts and aorta was isolated using 
TRI Reagent Solution (Invitrogen). Any DNA present 
was degraded using RQ1 RNAse-Free DNase 
(Promega) according to the manufacturer’s 
instructions. cDNA was synthesized using a High 
Capacity cDNA Reverse Transcription kit with RNase 
inhibitor (Invitrogen). qRT-PCR was performed using 
Fast SYBR Green Master Mix (Applied Biosystems) on 
the ABI7900 System (Applied Biosystems). Primers 
for 18s, prepro-ET-1, ETA and ETB receptors were 
generated. The amplification reaction mixture was 
heated at 95°C for 20s, then subject to 40 cycles of 95°C 
for 1s then 60°C for 20s. Values obtained for 
experimental gene measurements were normalized 
against expression of 18s.  
Statistical analysis 
Statistical analysis and data comparison for 
proteomics data were done using either Perseus or 
Excel software to classify the data using the two tailed 
Student t.test. In modeling software, p-value cutoff 
was 0.05 calculated with right-tailed Fisher Exact Test 
(Ingenuity®) and with Mann-Whitney U-test 
(Pathway Studio®). Data are expressed as mean ± 
SEM. Analyses were performed with Graphpad Prism 
(7.00). Unpaired and paired t tests were used to 
compare two data sets, one-way ANOVA was used to 
compare three data sets, and two-way ANOVA was 
used to compare three groups followed across time.  
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